1. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. Issue 3 (23rd February 2018) Authors: Thompson, Julie; Jones, Natasha; Al‐Khafaji, Ali; Malik, Shahid; Reich, David; Munoz, Santiago; MacNicholas, Ross; Hassanein, Tarek; Teperman, Lewis; Stein, Lance; Duarte‐Rojo, Andrés; Malik, Raza; Adhami, Talal; Asrani, Sumeet; Shah, Nikunj; Gaglio, Paul; Duddempudi, Anupama; Borg, Brian; Jalan,... Journal: Liver transplantation Issue: Volume 24:Issue 3(2018) Page Start: 380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FC 016SPARSENTAN IMPROVES GLOMERULAR BLOOD FLOW AND AUGMENTS PROTECTIVE TISSUE REMODELING IN MOUSE MODELS OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS). (29th May 2021) Authors: Gyarmati, Georgina; Shroff, Urvi; Izuhara, Audrey; Komers, Radko; Bedard, Patricia; Peti-Peterdi, Janos Journal: Nephrology dialysis transplantation Issue: Volume 36(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. MO255: Sparsentan Protects the Glomerular Basement Membrane and Glycocalyx, and Attenuates Proteinuria in a Rat Model of Focal Segmental Glomerulosclerosis (FSGS). (3rd May 2022) Authors: Bedard, Patricia; Jenkinson, Celia; Komers, Radko Journal: Nephrology dialysis transplantation Issue: Volume 37(2022)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗